EUR-Lex Access to European Union law
This document is an excerpt from the EUR-Lex website
Document 62010TB0573
Case T-573/10: Order of the General Court of 8 March 2012 — Octapharma Pharmazeutika v EMA (Medicinal products for human use — Changes to a plasma master file (PMF) — Fees payable to the EMA — Act with adverse effects — Measure merely confirmatory — Manifest inadmissibility)
Case T-573/10: Order of the General Court of 8 March 2012 — Octapharma Pharmazeutika v EMA (Medicinal products for human use — Changes to a plasma master file (PMF) — Fees payable to the EMA — Act with adverse effects — Measure merely confirmatory — Manifest inadmissibility)
Case T-573/10: Order of the General Court of 8 March 2012 — Octapharma Pharmazeutika v EMA (Medicinal products for human use — Changes to a plasma master file (PMF) — Fees payable to the EMA — Act with adverse effects — Measure merely confirmatory — Manifest inadmissibility)
SL C 126, 28.4.2012, p. 17–17
(BG, ES, CS, DA, DE, ET, EL, EN, FR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
- Date of document:
- 08/03/2012
- Date lodged:
- 23/12/2010
- Author:
- Opći sud
- Form:
- Pravosudna informacija
- Authentic language:
- njemački
- EUROVOC descriptor:
|
28.4.2012 |
EN |
Official Journal of the European Union |
C 126/17 |
Order of the General Court of 8 March 2012 — Octapharma Pharmazeutika v EMA
(Case T-573/10) (1)
(Medicinal products for human use - Changes to a plasma master file (PMF) - Fees payable to the EMA - Act with adverse effects - Measure merely confirmatory - Manifest inadmissibility)
2012/C 126/34
Language of the case: German
Parties
Applicant: Octapharma Pharmazeutika Produktionsgesellschaft mbH (Vienna, Austria) (represented by: I. Brinker and T. Holzmüller, lawyers, and J. Schwarze, Professor)
Defendant: European Medicines Agency (EMA) (represented by: V. Salvatore, acting as Agent, and H.-G. Kamann and P. Gey, lawyers)
Re:
Application for annulment of the letter of 21 October 2010 (EMA/643425/2010) by which the European Medicines Agency (EMA) refused to repay to the applicant the sum of EUR 180 700 corresponding to the difference between, on the one hand, the sum the applicant paid to it in respect of fees for the examination of variations to the terms of a marketing authorisation for medicinal products for human use and veterinary medicinal products and, on the other hand, the sum which the applicant maintains it should have paid.
Operative part of the order
|
1. |
The action is dismissed. |
|
2. |
Octapharma Pharmazeutika Produktionsgesellschaft mbH shall pay the costs. |
